Covered recipient · General Payments record
FRANCISCO JAVIER GOMEZ-DOSSI
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
General Payments · PY2018–2022
$68,595.83
- Reported across 224 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2022 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $4,512.50 | 1 |
| Travel and Lodging | $959.40 | 1 |
| Food and Beverage | $127.42 | 7 |
By paying entity
PY2022 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ARGENX US, INC. | $5,471.90 | 2 |
| GENZYME CORPORATION | $38.12 | 2 |
| ABBVIE INC. | $26.50 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $19.63 | 1 |
| Alexion Pharmaceuticals, Inc. | $17.50 | 1 |
| Genentech USA, Inc. | $13.81 | 1 |
| Celgene Corporation | $11.86 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2022 (9)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $26.50 | 01/28/2022 | Food and Beverage | Undisputed | 01/23/2026 | 891052857 | CMS |
| Alexion Pharmaceuticals, Inc. | $17.50 | 03/02/2022 | Food and Beverage | Undisputed | 01/23/2026 | 915490903 | CMS |
| ARGENX US, INC. | $959.40 | 06/27/2022 | Travel and Lodging | Undisputed | 01/23/2026 | 951641649 | CMS |
| ARGENX US, INC. | $4,512.50 | 06/27/2022 | Consulting Fee | Undisputed | 01/23/2026 | 951641651 | CMS |
| Celgene Corporation | $11.86 | 05/02/2022 | Food and Beverage | Undisputed | 01/23/2026 | 932595675 | CMS |
| Genentech USA, Inc. | $13.81 | 05/18/2022 | Food and Beverage | Undisputed | 01/23/2026 | 950773499 | CMS |
| GENZYME CORPORATION | $19.31 | 02/17/2022 | Food and Beverage | Undisputed | 01/23/2026 | 938805035 | CMS |
| GENZYME CORPORATION | $18.81 | 03/16/2022 | Food and Beverage | Undisputed | 01/23/2026 | 938805041 | CMS |
| Novartis Pharmaceuticals Corporation | $19.63 | 02/03/2022 | Food and Beverage | Undisputed | 01/23/2026 | 893707683 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022
- Generated from
- OP_DTL_GNRL_PGYR2022_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.